Great business models. Great growth prospects. Great moats. These three stocks check off all the boxes for buying and holding for years to come.
News & Analysis: Vertex Pharmaceuticals
The pharma and biotech industries are high risk. But Vertex Pharmaceuticals is boldly soldiering on and wisely investing where it has a competitive advantage.
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff
The biotech just announced a potentially game-changing acquisition.
These healthcare winners have such strong competitive advantages that their theme song could be MC Hammer's "U Can't Touch This."
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
Two great biotechs focused on rare diseases. But one of them gets the nod as the better pick.
Investors know it's not easy to find companies already worth tens of billions that can still expand their revenues rapidly. But these giants show it's not impossible.
A dominant cystic fibrosis franchise drives cash flow.
Find out how concerned Vertex investors should be about a potential new cystic fibrosis treatment.
VRTX earnings call for the period ending June 30, 2019.